Akero Therapeutics Inc.

12.75-0.2200-1.70%Vol 156.24K1Y Perf -31.12%
Aug 16th, 2022 16:00 DELAYED
BID8.50 ASK13.58
Open12.86 Previous Close12.97
Pre-Market- After-Market12.75
 - -  - -%
Target Price
40.75 
Analyst Rating
Moderate Buy 1.80
Potential %
219.61 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
26.88 
Earnings Rating
Market Cap479.03M 
Earnings Date
12th Aug 2022
Alpha-0.01 Standard Deviation0.14
Beta0.62 

Today's Price Range

12.540.00

52W Range

7.5226.98

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-7.21%
1 Month
15.49%
3 Months
35.64%
6 Months
-30.59%
1 Year
-31.12%
3 Years
-51.59%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AKRO12.75-0.2200-1.70
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.85-0.779.41
Q01 2022-0.85-0.7412.94
Q04 2021-0.81-0.93-14.81
Q03 2021-0.91-0.7023.08
Q02 2021-0.72-0.83-15.28
Q01 2021-1.01-0.4357.43
Q04 2020-0.72-0.86-19.44
Q03 2020-0.48-0.63-31.25
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.85
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume156.24K
Shares Outstanding37.57K
Shares Float30.30M
Trades Count3.48K
Dollar Volume1.99M
Avg. Volume268.73K
Avg. Weekly Volume189.74K
Avg. Monthly Volume250.53K
Avg. Quarterly Volume365.93K

Akero Therapeutics Inc. (NASDAQ: AKRO) stock closed at 12.75 per share at the end of the most recent trading day (a -1.7% change compared to the prior day closing price) with a volume of 156.24K shares and market capitalization of 479.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Akero Therapeutics Inc. CEO is Andrew Cheng.

The one-year performance of Akero Therapeutics Inc. stock is -31.12%, while year-to-date (YTD) performance is -39.72%. AKRO stock has a five-year performance of %. Its 52-week range is between 7.52 and 26.98, which gives AKRO stock a 52-week price range ratio of 26.88%

Akero Therapeutics Inc. currently has a PE ratio of -4.20, a price-to-book (PB) ratio of 3.37, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -52.01%, a ROC of -57.85% and a ROE of -59.80%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Akero Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.85 for the next earnings report. Akero Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Akero Therapeutics Inc. is Moderate Buy (1.8), with a target price of $40.75, which is +219.61% compared to the current price. The earnings rating for Akero Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akero Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akero Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 19.36, ATR14 : 0.96, CCI20 : 86.53, Chaikin Money Flow : -0.03, MACD : 0.70, Money Flow Index : 69.83, ROC : 26.54, RSI : 53.62, STOCH (14,3) : 72.26, STOCH RSI : 0.13, UO : 56.77, Williams %R : -27.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akero Therapeutics Inc. in the last 12-months were: Andrew Cheng (Option Excercise at a value of $51 045), Andrew Cheng (Sold 90 000 shares of value $1 894 650 ), Catriona Yale (Sold 25 000 shares of value $578 431 ), Jonathan Young (Option Excercise at a value of $17 063), Jonathan Young (Sold 37 500 shares of value $907 623 ), William R. White (Option Excercise at a value of $242 224), William R. White (Sold 34 559 shares of value $779 762 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (60.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (40.00 %)
1 (25.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.80
Strong Buy
1.50
Strong Buy
1.50

Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

CEO: Andrew Cheng

Telephone: +1 650 487-6488

Address: 170 Harbor Way, South San Francisco 94080, CA, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

77%23%

Bearish Bullish

64%36%

TipRanks News for AKRO

Fri, 22 Jul 2022 09:37 GMT Akero Therapeutics (AKRO) was Downgraded to a Hold Rating at Evercore ISI

- TipRanks. All rights reserved.

News

Stocktwits